publication date: Dec. 18, 2010
In this issue:
After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.
Amgen Claimed QOL Benefit Despite FDA Label Change.
“Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising.
FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.
CMS Proposal To Limit ESA Use Is Too Much, Too Fast, Critics Say.
Download (PDF 849KB)
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.